Idiopathic pulmonary fibrosis (IPF) affects approximately 15,000 people in Canada, 100,000 in the United States, and 200,000 in Europe, while nonalcoholic steatohepatitis (NASH) affects approximately 38 million Americans, 10 million Europeans, and 1.5 million Canadians.
Professor Denis Giguère, from the Department of Chemistry at Université Laval, an expert in carbohydrate chemistry and complex molecule design, has developed a breakthrough technology to address certain pharmacological limitations and improve the selectivity of galectin-3. Leveraging Glycovax’s expertise and its exclusive worldwide license, the program is now entering an acceleration phase aimed at advancing toward the identification of high-potential therapeutic applications with strong clinical relevance.